Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T19:41:06.902Z.
Calculation as of: 2026-10-06T19:41:06.902Z.
Quote observation: 2026-10-06T19:40:18.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ea268c636d02c1563f9a0cc17fa45ef3048b6802d4031696aa30e1bc9d7aaf2a
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Connect Biopharma Holdings Limited
Market Cap
$57.18M
EBITDA Yield
N/A
| NAME | MARKET CAP | EBITDA YIELD |
|---|---|---|
| Connect Biopharma Holdings Limited (CNTB) | $57.18M | N/A |
| Talphera, Inc. (TLPH)vs › | $57.87M | N/A |
| PDS Biotechnology Corporation (PDSB)vs › | $57.88M | N/A |
| Boundless Bio, Inc. (BOLD)vs › | $57.98M | N/A |
| Xilio Therapeutics, Inc. (XLO)vs › | $58.85M | N/A |
| MiNK Therapeutics, Inc. (INKT)vs › | $58.94M | N/A |
| Adicet Bio, Inc. (ACET)vs › | $59.03M | N/A |
| OKYO Pharma Limited (OKYO)vs › | $56.02M | N/A |
| Fractyl Health, Inc. (GUTS)vs › | $60.02M | N/A |
| Oncolytics Biotech Inc. (ONCY)vs › | $60.05M | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
